The Value Signal — October 28, 2026

715 articles scanned · 12 high-signal

Signal Map

Executive Summary

Medicare Advantage's quality-and-network machinery is now being contested in court and stress-tested by mass plan exits, while CMS presses ahead on new mandates that providers say they are not ready to absorb.

On Star Ratings, the fight has moved to litigation. Modern Healthcare reports that Aetna is suing over a $2 billion Medicare Advantage star ratings loss, even as Centene posts an early MA rebound. Becker's Payer notes that Centene has filed its own suit, claiming CMS' 2027 star ratings will cost it $448 million. On Medicare market churn, KFF finds that 4.3 million beneficiaries, including 3.1 million Medicare Advantage drug plan enrollees and 1.2 million stand-alone PDP enrollees, will have their plans terminated at the end of 2026. KFF also warns that immigration-related fears are leading some immigrant families to avoid care and drop coverage, a coverage-erosion risk for risk-bearing entities.

On the regulatory front, ASM timing is under pressure: MGMA is urging CMS to delay the model's launch. For Prior Authorization, Forvis Mazars details how organizations must adapt workflows to meet the CMS-0057-F API requirements, signaling that operational readiness is the binding constraint. On Medicaid, the AMA reports that physician organizations are backing a new legal challenge to the Medicaid work rule. Oversight remains aggressive, with HHS OIG announcing a 20-year prison sentence for a telemedicine company owner behind a $46 million Medicare fraud scheme.